Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDNA NASDAQ:NTRA NYSE:NVTA NASDAQ:RDNT NASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDNACareDx$14.74+2.4%$13.58$10.96▼$31.52$784.67M2.371.21 million shs68,072 shsNTRANatera$173.89+2.7%$164.58$117.27▼$183.00$23.81B1.741.43 million shs70,997 shsNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shs75 shsRDNTRadNet$71.06+0.7%$70.71$45.00▼$93.65$5.47B1.59792,080 shs25,659 shsVCYTVeracyte$34.58-0.6%$31.36$22.61▼$47.32$2.72B2.111.12 million shs46,843 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDNACareDx0.00%-5.27%+6.36%-28.12%-53.00%NTRANatera0.00%+1.15%+0.45%+7.01%+30.15%NVTAInvitae0.00%0.00%0.00%0.00%0.00%RDNTRadNet0.00%-9.07%-4.61%+24.76%+2.95%VCYTVeracyte0.00%-3.33%+12.69%+30.58%+2.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDNACareDx$14.74+2.4%$13.58$10.96▼$31.52$784.67M2.371.21 million shs68,072 shsNTRANatera$173.89+2.7%$164.58$117.27▼$183.00$23.81B1.741.43 million shs70,997 shsNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shs75 shsRDNTRadNet$71.06+0.7%$70.71$45.00▼$93.65$5.47B1.59792,080 shs25,659 shsVCYTVeracyte$34.58-0.6%$31.36$22.61▼$47.32$2.72B2.111.12 million shs46,843 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDNACareDx0.00%-5.27%+6.36%-28.12%-53.00%NTRANatera0.00%+1.15%+0.45%+7.01%+30.15%NVTAInvitae0.00%0.00%0.00%0.00%0.00%RDNTRadNet0.00%-9.07%-4.61%+24.76%+2.95%VCYTVeracyte0.00%-3.33%+12.69%+30.58%+2.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDNACareDx 2.38Hold$25.5073.00% UpsideNTRANatera 2.90Moderate Buy$192.8810.92% UpsideNVTAInvitae 0.00N/AN/AN/ARDNTRadNet 2.88Moderate Buy$76.808.08% UpsideVCYTVeracyte 2.67Moderate Buy$40.9018.28% UpsideCurrent Analyst Ratings BreakdownLatest NVTA, VCYT, NTRA, CDNA, and RDNT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025CDNACareDxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/8/2025NTRANateraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025RDNTRadNetWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025VCYTVeracyteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/6/2025VCYTVeracyteZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/27/2025CDNACareDxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025NTRANateraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025RDNTRadNetWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025VCYTVeracyteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/23/2025CDNACareDxBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.009/22/2025NTRANateraWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageEqual Weight$175.00(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDNACareDx$340.83M2.30$1.39 per share10.58$7.06 per share2.09NTRANatera$1.70B14.06N/AN/A$9.05 per share19.21NVTAInvitae$481.58M0.00N/AN/A$0.42 per share0.00RDNTRadNet$1.83B2.99$3.51 per share20.27$15.31 per share4.64VCYTVeracyte$479.13M5.68$1.03 per share33.56$15.17 per share2.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDNACareDx$52.55M$1.0214.45N/AN/A17.97%18.03%12.88%11/3/2025 (Estimated)NTRANatera-$190.43M-$1.91N/AN/AN/A-12.89%-22.22%-15.03%11/11/2025 (Estimated)NVTAInvitae-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/ARDNTRadNet$2.79M-$0.20N/A134.08N/A-0.78%2.41%0.82%11/10/2025 (Estimated)VCYTVeracyte$24.14M$0.33104.7948.03N/A5.50%6.07%5.53%11/5/2025 (Estimated)Latest NVTA, VCYT, NTRA, CDNA, and RDNT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/10/2025Q3 2025RDNTRadNet$0.23N/AN/AN/A$494.19 millionN/A11/5/2025Q3 2025VCYTVeracyte$0.32N/AN/AN/A$124.62 millionN/A11/3/2025Q3 2025CDNACareDx$0.13N/AN/AN/AN/AN/A8/10/2025Q2 2025RDNTRadNet$0.17$0.31+$0.14$0.43$488.06 million$498.23 million8/7/2025Q2 2025NTRANatera-$0.60-$0.74-$0.14-$0.74$476.84 million$546.60 million8/6/2025Q2 2025CDNACareDx$0.12-$0.16-$0.28-$0.16$90.72 million$90.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDNACareDxN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/ANVTAInvitaeN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDNACareDxN/A3.303.00NTRANateraN/A3.723.58NVTAInvitaeN/A2.392.25RDNTRadNet0.912.002.00VCYTVeracyteN/A5.435.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDNACareDxN/ANTRANatera99.90%NVTAInvitae61.28%RDNTRadNet77.90%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipCDNACareDx4.40%NTRANatera5.63%NVTAInvitae0.74%RDNTRadNet5.60%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDNACareDx74053.23 million50.89 millionOptionableNTRANatera4,434137.25 million129.52 millionOptionableNVTAInvitae1,700267.01 million284.37 millionOptionableRDNTRadNet11,02176.92 million72.61 millionOptionableVCYTVeracyte79078.67 million77.57 millionOptionableNVTA, VCYT, NTRA, CDNA, and RDNT HeadlinesRecent News About These CompaniesVeracyte's (VCYT) Sell (D+) Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Upgraded to "Strong-Buy" at Zacks ResearchOctober 8, 2025 | marketbeat.comInsider Selling: Veracyte (NASDAQ:VCYT) Insider Sells 8,349 Shares of StockOctober 8, 2025 | insidertrades.comVeracyte (NASDAQ:VCYT) Insider Sells 8,349 SharesOctober 7, 2025 | marketbeat.comThis Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your RadarOctober 7, 2025 | zacks.comVeracyte (VCYT): Reassessing Valuation After New BALANCE Trial Data Highlights Decipher’s Clinical ImpactOctober 6, 2025 | finance.yahoo.comWilliam Blair Reaffirms Their Buy Rating on Veracyte (VCYT)October 4, 2025 | theglobeandmail.comBrokerages Set Veracyte, Inc. (NASDAQ:VCYT) Price Target at $40.90October 4, 2025 | americanbankingnews.comAMI Asset Management Corp Sells 8,580 Shares of Veracyte, Inc. $VCYTOctober 2, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Given Average Recommendation of "Moderate Buy" by AnalystsOctober 1, 2025 | marketbeat.comWhy Veracyte (VCYT) is a Top Momentum Stock for the Long-TermSeptember 29, 2025 | zacks.comVeracyte announces results from BALANCE trial of PAM50September 29, 2025 | msn.comVeracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate CancerSeptember 28, 2025 | businesswire.comVeracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025September 24, 2025 | finance.yahoo.comAnnie Mcguire Sells 2,283 Shares of Veracyte (NASDAQ:VCYT) StockSeptember 24, 2025 | insidertrades.comVoya Investment Management LLC Increases Stock Holdings in Veracyte, Inc. $VCYTSeptember 24, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) SVP Annie Mcguire Sells 2,283 SharesSeptember 23, 2025 | marketbeat.comAssenagon Asset Management S.A. Raises Stock Holdings in Veracyte, Inc. $VCYTSeptember 22, 2025 | marketbeat.comExchange Traded Concepts LLC Purchases 23,047 Shares of Veracyte, Inc. $VCYTSeptember 21, 2025 | marketbeat.comStrs Ohio Takes Position in Veracyte, Inc. $VCYTSeptember 20, 2025 | marketbeat.comAQR Capital Management LLC Lowers Stock Position in Veracyte, Inc. $VCYTSeptember 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines2 Falling Knives That Might Be Worth CatchingBy Sam Quirke | September 16, 20253 Defense Stocks Surging as Ukraine Tensions DeepenBy Dan Schmidt | October 5, 2025General Dynamics Hits New Highs: Why It Might Keep ClimbingBy Jeffrey Neal Johnson | October 2, 2025Rocket Lab's Electron: The Quiet Workhorse Powering MomentumBy Ryan Hasson | October 2, 2025Lululemon’s Sell-Off Looks Overdone: A Contrarian CaseBy Sam Quirke | September 16, 2025NVTA, VCYT, NTRA, CDNA, and RDNT Company DescriptionsCareDx NASDAQ:CDNA$14.74 +0.35 (+2.43%) As of 10:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Natera NASDAQ:NTRA$173.89 +4.62 (+2.73%) As of 10:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Invitae NYSE:NVTAInvitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.RadNet NASDAQ:RDNT$71.06 +0.46 (+0.65%) As of 10:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.Veracyte NASDAQ:VCYT$34.58 -0.22 (-0.63%) As of 10:20 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Microsoft 365 Premium Marks the Next Phase of AI Monetization 3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
